Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Illingworth
D R
DR
Department of Medicine, Oregon Health Sciences University, Portland.
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use; D017035:Pravastatin; D019821:Simvastatin
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009281:Naphthalenes; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin